Autres langues Galmed Pharmaceuticals Ltd.

Actions

GLMD

IL0011313900

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 13/06/2025			Varia. 5j.	Varia. 1 janv.
1,600 ^USD	-0,62 %		+5,96 %	-49,84 %

27/05	Galmed identifie une signature biomarqueur exclusive pour l'Aramchol, ouvrant la voie à un potentiel d'expansion de plusieurs milliards de dollars au-delà de la NASH	CI
22/05	Galmed Pharmaceuticals Ltd. publie ses résultats financiers pour le premier trimestre clos le 31 mars 2025	CI

Autres langues

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash	27/05
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH	27/05
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update	23/05
Galmed Pharmaceuticals: Q1 Earnings Snapshot	22/05
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	22/05
Galmed Pharmaceuticals Ltd. Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models	13/05
Galmed Announces First Time Results In Oncology Studies Aramchol Significantly Enhances Bayer's Regorafenib Effect In Gi Cancer Models	06/05
Galmed Pharmaceuticals Ltd. Announces First Time Results in Oncology Studies	06/05
Top Midday Gainers	28/04
Galmed Signs Term Sheet to Develop New Semaglutide Formulation; Shares Up	28/04
Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation	28/04
Galmed Pharmaceuticals Ltd. Signs Term Sheet for the Development of Novel Semaglutide Sublingual Formulation	28/04
Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers	17/04
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers	17/04
Galmed Pharmaceuticals Launches Vcu Collaboration to Tackle Drug Resistance in GI Cancers	17/04
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor	15/04
Galmed Pharmaceuticals Ltd. Unveils Novel Pharmacodynamic Blood Markers for Aramchol	15/04
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor	10/04
Galmed Pharmaceuticals Ltd. Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor	10/04
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024	02/04
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	02/04
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy	20/03
Galmed Pharmaceuticals Ltd. Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in Nash/Mash Combination Therapy	20/03
Galmed Pharmaceuticals: Q3 Earnings Snapshot	15/11
Galmed Pharmaceuticals : Sales Agreement Form 6 K	15/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Galmed Pharmaceuticals Ltd.

Actions

GLMD

IL0011313900

Recherche biotechnologique et médicale

Autres langues

Filtres